KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia
Version of Record online: 4 FEB 2013
© 2013 Blackwell Publishing Ltd
British Journal of Haematology
Volume 161, Issue 1, pages 117–127, April 2013
How to Cite
Etchin, J., Sanda, T., Mansour, M. R., Kentsis, A., Montero, J., Le, B. T., Christie, A. L., McCauley, D., Rodig, S. J., Kauffman, M., Shacham, S., Stone, R., Letai, A., Kung, A. L. and Thomas Look, A. (2013), KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. British Journal of Haematology, 161: 117–127. doi: 10.1111/bjh.12231
- Issue online: 15 MAR 2013
- Version of Record online: 4 FEB 2013
- Manuscript Accepted: 19 NOV 2012
- Manuscript Received: 11 SEP 2012
- William Lawrence and Hughes Blanche Foundation
- Karyopharm Therapeutics Incorporated, Alex's Lemonade Stand
- Leukemia and Lymphoma Society Translational grant
- National Cancer Institute. Grant Number: 1K99CA157951
- Children's Leukemia Research Association
- Japan Society for the Promotion of Science
- Kay Kendall Leukaemia Fund
- NIH. Grant Number: K08CA160660
Fig S1. KPT-330 induces cell death in T-ALL cells.
Fig S2. KPT-330 promotes rapid apoptotic cell death in T-ALL cells.
Fig S3. Treatment with KPT-330 leads to cell cycle arrest in G1 phase.
Fig S4. Progression of leukemia prior to the start of treatment.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.